IA期G2子宫内膜样癌保留生育功能的标准化治疗结局
本研究评估了IA期G2子宫内膜样癌无肌层浸润患者采用宫腔镜切除联合孕激素治疗的肿瘤与生殖结局。25例患者完全缓解率100%,6个月时84%缓解,复发率56%,60%尝试妊娠者中53.3%成功怀孕。结论支持在严格筛选患者中使用该方案。
要点
- 宫腔镜切除联合MA 160mg/日及LNG-IUD方案完全缓解率100%。
- 中位6个月达完全缓解,但复发率56%,中位复发时间16.6个月。
- 60%患者尝试妊娠,其中53.3%成功怀孕,活产与持续妊娠各3例。
核心结论
- 标准化保留生育方案在IA期G2子宫内膜样癌无肌层浸润患者中有效且安全,生殖结局良好。
研究设计与样本
- 单中心回顾性队列研究,纳入2019年6月至2024年8月连续25例IA期G2子宫内膜样癌无肌层浸润患者。
- 所有患者接受宫腔镜切除后联合口服醋酸甲地孕酮160mg/日及左炔诺孕酮宫内节育系统治疗。
主要发现
- 完全缓解率100%(25/25),6个月时84%达完全缓解,中位达完全缓解时间6个月(范围6-12)。
- 复发率56.0%(14/25),中位复发时间16.6个月;6例接受根治性手术,8例再次保守治疗成功且无病。
- 末次随访时24/25(96%)无疾病证据;95.4%为错配修复功能正常,无p53突变,ER/PR高表达,所有检测病例存在β-catenin突变。
- 未观察到治疗相关并发症。
临床怎么用
- 该方案可作为严格筛选的IA期G2子宫内膜样癌无肌层浸润患者保留生育功能的选择。
- 需密切随访监测复发,复发后仍可考虑再次保守治疗。
局限性
- 样本量小(25例),随访时间有限,需更长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate oncologic and reproductive outcomes of fertility-sparing treatment in women with stage IA grade 2 endometrioid endometrial cancer (EEC) without myometrial invasion treated with a standardized protocol. METHODS: Consecutive women diagnosed with stage IA grade 2 EEC without myometrial invasion between June 2019 and August 2024 at a single tertiary center were treated with hysteroscopic resection followed by combined progestin therapy with oral megestrol acetate (MA) 160 mg/day and a levonorgestrel intrauterine device (LNG-IUD). RESULTS: Twenty-five patients were included; median follow-up was 33 (IQR 12-90) months and median age 34 years (IQR 20-41). Complete response (CR) was achieved in 100% (25/25), with 84% at 6 months. Median time to CR was 6 months (range 6-12). Fifteen patients (60%) attempted conception, and 8 (53.3%) achieved pregnancy. Three delivered at term, three pregnancies are ongoing, and two resulted in miscarriage. Recurrence occurred in 56.0% (14/25) with a median time of 16.6 months. Six patients underwent definitive surgery, while eight were successfully retreated conservatively and are disease-free. Overall, 24/25 (96%) showed no evidence of disease at last follow-up. Most tumors were mismatch repair proficient (95.4%), none p53-mutated, with high ER/PR expression. All tested cases harbored β-catenin mutations. No treatment-related complications were observed. CONCLUSIONS: A standardized fertility-sparing approach combining hysteroscopic resection and progestins achieved effective and safe management in stage IA grade 2 EEC without myometrial invasion, with favorable reproductive outcomes. These findings support its use in carefully selected patients, although longer follow-up is needed.
引用
- Catena U, Dinoi G, Masciullo V, et al. Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach. Gynecol Oncol. 2026. PMID: 42419001. doi:10.1016/j.ygyno.2026.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。